Today's Market Winners and Losers

Before you go, we thought you'd like these...
Before you go close icon

TradersThe stock market is mixed Tuesday, with the Dow Jones Industrial Average up 0.27%, the Nasdaq down 0.35% and the S&P 500 up 0.13%. Today's winners are a biopharmaceutical company that continues to see its shares rise on a positive drug trial result and an oil company with a major shareholder that plans to nominate directors to boost returns. Today's losers are a technology company reporting a poor 2013 outlook and another pharmaceutical company reporting disappointing trial results for a treatment.

These are Tuesday's market winners and losers.

Biggest Winners

Shares of Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) are up 37.05% on trading volume of 24.2 million shares. The stock continues to jump after positive reports regarding the company's kidney drug. Before Tuesday, the 52-week high was $6.86.

Shares of Hess Corp. (NYSE: HES) are up 9.33% to $68.31 on trading volume of 10.3 million shares. Elliott Management announced it plans to nominate five executives to the board to help boost shareholder returns. Before Tuesday, the 52-week high was $67.86.

Biggest Losers

Shares of VMWare Inc. (NYSE: VMW) are down 19.66% to $78.99 on trading volume of 13.1 million shares. The company announced in its fourth-quarter earnings presentation that it would likely earn $1.85 a share, below the $1.90 expected by analysts polled by Reuters. Before Tuesday, the 52-week low was $79.46.

Shares of Anacor Pharmaceuticals Inc. (NASDAQ: ANAC) are down 17.79% to $4.25 on trading volume of 4.2 million shares. The shares fell following disappointing results on a test for toenail fungus therapy. Before Tuesday, the 52-week low was $4.50.

Follow Samuel on Twitter: SWeigley


Filed under: 24/7 Wall St. Wire Tagged: ANAC, HES, KERX, VMW
Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners